BioStock: BioInvent selected to present at ASCO in Chicago

BioInvent has been selected to present two posters at the American Society for Clinical Oncology Annual Congress (ASCO 2024) in Chicago from May 31 to June 4. The presentations will focus on data from the company’s clinical studies with the lead drug candidates BI-1808 and BI-1206, both in phase I/IIa development in combination with MSD’s Keytruda. BI-1808 is also evaluated as single agent, which will also be included in the presentation.

Read the article at biostock.se:

https://www.biostock.se/en/2024/04/bioinvent-selected-to-present-at-asco-in-chicago/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/